[ back to News ]

Concert Pharmaceuticals to Present at the Piper Jaffray Health Care Conference

November 24 , 2008

LEXINGTON, MA -- Concert Pharmaceuticals, Inc. announced today that it will be presenting at the 20th Annual Piper Jaffray Health Care Conference, being held at The New York Palace in New York City. Roger Tung, Ph.D., President and Chief Executive Officer of Concert, will present an overview of the Company on Tuesday, December 2, 2008 at 3:30 p.m. (ET).

About Concert

Concert Pharmaceuticals, Inc. is a clinical stage biotechnology company dedicated to creating medically and commercially important new medicines through a novel approach utilizing the naturally-occurring element deuterium. Concert applies its innovative platform to create highly differentiated compounds based on well-understood biological targets and drug molecules, yielding a rich pipeline of new chemical entities (NCEs). By leveraging decades of pharmaceutical experience to design NCEs from proven therapies, Concert’s drug candidates have potential for first-in-class use in under-served medical conditions, as well as best-in-class efficacy and safety, while reducing R&D risk, time, and expense. The Company has over 100 patent applications for new drug candidates addressing a broad range of therapeutic areas, including vasomotor symptoms, HIV/AIDS and fibrotic diseases, among others. Since its inception in 2006, Concert has raised more than $96 million and has been financed by leading venture capitalists and institutional investors. A listing of Concert’s institutional shareholders and additional corporate information is available online at http://www.concertpharma.com.

CoNCERT and CoNCERT Pharmaceuticals are trademarks of Concert Pharmaceuticals, Inc.

[ back to top ]